These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 7742525)
61. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971 [TBL] [Abstract][Full Text] [Related]
62. A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia. Kheradpour A; Berman E; Göker E; Lin JT; Tong WP; Bertino JR Cancer Invest; 1995; 13(1):36-40. PubMed ID: 7834472 [TBL] [Abstract][Full Text] [Related]
63. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates. Goldman ID; Matherly LH NCI Monogr; 1987; (5):17-26. PubMed ID: 2448654 [TBL] [Abstract][Full Text] [Related]
64. Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line. Gong M; Yess J; Connolly T; Ivy SP; Ohnuma T; Cowan KH; Moscow JA Blood; 1997 Apr; 89(7):2494-9. PubMed ID: 9116294 [TBL] [Abstract][Full Text] [Related]
65. Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: potentiating or reversing effect? Van der Wilt CL; Braakhuis BJ; Pinedo HM; De Jong M; Smid K; Peters GJ Int J Cancer; 1995 May; 61(5):672-8. PubMed ID: 7768641 [TBL] [Abstract][Full Text] [Related]
66. Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2. Romanini A; Sobrero AF; Chou TC; Sherwood RF; Bertino JR Cancer Res; 1989 Nov; 49(21):6019-23. PubMed ID: 2529027 [TBL] [Abstract][Full Text] [Related]
67. Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. Shuper A; Stark B; Kornreich L; Cohen IJ; Avrahami G; Yaniv I Isr Med Assoc J; 2002 Nov; 4(11):1050-3. PubMed ID: 12489505 [TBL] [Abstract][Full Text] [Related]
68. A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Jolivet J; Landry L; Pinard MF; McCormack JJ; Tong WP; Eisenhauer E Cancer Chemother Pharmacol; 1987; 20(2):169-72. PubMed ID: 2959389 [TBL] [Abstract][Full Text] [Related]
69. Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay. Rots MG; Pieters R; Kaspers GJ; van Zantwijk CH; Noordhuis P; Mauritz R; Veerman AJ; Jansen G; Peters GJ Blood; 1999 Feb; 93(3):1067-74. PubMed ID: 9920857 [TBL] [Abstract][Full Text] [Related]
70. Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer. Punt CJ; Blanke CD; Zhang J; Hammershaimb L Ann Oncol; 2002 Jan; 13(1):92-4. PubMed ID: 11865815 [TBL] [Abstract][Full Text] [Related]
71. Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines. Mini E; Moroson BA; Franco CT; Bertino JR Cancer Res; 1985 Jan; 45(1):325-30. PubMed ID: 3855284 [TBL] [Abstract][Full Text] [Related]
72. The role of folates in the development of methotrexate resistance in human leukemia cell line K562. Miyachi H; Takemura Y; Ando Y; Scanlon KJ J Cancer Res Clin Oncol; 1992; 119(2):101-5. PubMed ID: 1429825 [TBL] [Abstract][Full Text] [Related]
73. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group. Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605 [TBL] [Abstract][Full Text] [Related]
74. Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. Hudes GR; LaCreta F; DeLap RJ; Grillo-Lopez AJ; Catalano R; Comis RL Cancer Chemother Pharmacol; 1989; 24(2):117-22. PubMed ID: 2525077 [TBL] [Abstract][Full Text] [Related]
75. Differential calcium leucovorin protection of human lymphoid cell lines from methotrexate. Browman GP; Booker L; Spiegl P Cancer Chemother Pharmacol; 1985; 15(2):105-10. PubMed ID: 2410158 [TBL] [Abstract][Full Text] [Related]
76. An assay for the determination of reduced methotrexate accumulation in cells displaying limited viability in vitro. Haber M; Norris MD; Kavallaris M; Camacho M; Madafiglio J; Baker CJ; White L; Stewart BW Cancer Lett; 1995 Oct; 97(1):49-55. PubMed ID: 7585477 [TBL] [Abstract][Full Text] [Related]
77. Pharmacokinetic study of trimetrexate in combination with cisplatin. Hudes GR; LaCreta F; Walczak J; Tinsley P; Litwin S; Comis RL; O'Dwyer PJ Cancer Res; 1991 Jun; 51(12):3080-7. PubMed ID: 1828188 [TBL] [Abstract][Full Text] [Related]
78. 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism. McGuire JJ; Haile WH; Yeh CC Cancer Res; 2006 Apr; 66(7):3836-44. PubMed ID: 16585211 [TBL] [Abstract][Full Text] [Related]
79. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. Rhee MS; Galivan J; Wright JE; Rosowsky A Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264 [TBL] [Abstract][Full Text] [Related]
80. 5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines. Pizzorno G; Cashmore AR; Moroson BA; Cross AD; Smith AK; Marling-Cason M; Kamen BA; Beardsley GP J Biol Chem; 1993 Jan; 268(2):1017-23. PubMed ID: 8419310 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]